清脆的
计算生物学
基因组编辑
逆转录酶
DNA
生物
Cas9
遗传学
核糖核酸
基因
作者
Y. Bill Kim,Elizabeth B. Pierce,Michael S. Brown,Brenda A. Peterson,Derek Sanford,Justin M. Fear,David Nicholl,Ellyce San Pedro,Grace M. Reynolds,Joanne E. Hunt,David G. Schwark,Sathya Jali,Nathaniel Graham,Zoe Cesarz,Tracey A. Lincoln Chapman,Joseph Watts,Aaron W. Hummel
标识
DOI:10.1101/2022.12.13.520319
摘要
ABSTRACT CRISPR/Cas systems coupled with reverse transcriptase (RT), such as the recently described Prime editing, allow for site-specific replacement of DNA sequences. Despite widespread testing of Prime editing, it is currently only compatible with type II CRISPR/Cas proteins such as Streptococcus pyogenes and Staphylococcus aureus Cas9. Enabling RT compatibility with other CRISPR/Cas domains, such as type V enzymes with orthogonal protospacer adjacent motif specificities and smaller protein size would expand the range of edits that can be made in therapeutic and industrial applications. We achieve this with a novel mode of DNA editing at CRISPR-targeted sites that reverse transcribes the edit into the target strand DNA (e.g., the complement of the PAM-containing strand), rather than the non-target strand DNA, as in Prime editing. We term this technology R NA encoded D NA r eplacement of a lleles w ith CRISPR (hereafter, REDRAW). We show that REDRAW extends the utility of RT-mediated editing beyond type II to include multiple type V CRISPR domains. REDRAW features a broad (8-10 bases) targeting window, at which all types of substitutions, insertions and deletions are possible. REDRAW combines the advantages of type V CRISPR domains with the extensive range of genetic variation enabled by RT-mediated, templated sequence replacement strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI